Loading
A phase 2 trial of TQB2450, Anlotinib in non-small-cell lung cancer and small-cell lung cancer, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.
A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05913089 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 58 participants planned, started 2023-06-14 and due to reach its primary completion in 2026-06. Interventions recorded: TQB2450 injection + Chemotherapy, TQB2450 injection + Anlotinib Hydrochloride Capsule. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Anlotinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Anlotinib, Anti-angiogenic therapy, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Anlotinib, Anti-angiogenic therapy, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Anlotinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Small-molecule kinase inhibitors.